HemaQuest Pharmaceuticals Secures $12,000,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ac04b182-ad45-419c-9938-894c276e9ebc&Preview=1 -
Date
4/22/2010 -
Company Name
HemaQuest Pharmaceuticals -
Mailing Address
1229 Madison Street Seattle, WA 98104 -
Company Description
HemaQuest is a company developing proprietary small molecule therapeutics to treat serious blood disorders. -
Website
http://www.hemaquest.com -
Transaction Type
Venture Equity -
Transaction Amount
$12,000,000 -
Transaction Round
Series B -
Proceeds Purposes
The financing is intended to help advance HemaQuest’s two lead products, HQK-1001 and HQK-1004, into pre-pivotal Phase 2 clinical trials. -
M&A Terms
-
Venture Investor
Aberdare Ventures -
Venture Investor
De Novo Ventures -
Venture Investor
Forward Ventures -
Venture Investor
Lilly Ventures
